4.6 Review

Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer

期刊

CANCER TREATMENT REVIEWS
卷 37, 期 8, 页码 611-617

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2011.04.003

关键词

Angiogenesis; NSCLC; TKIs; VEGFR; PDGFR; FGFR

类别

资金

  1. Genentech
  2. Lilly
  3. Pfizer
  4. Celgene
  5. Synta Pharmaceuticals
  6. Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

向作者/读者索取更多资源

In the United States, the leading cause of cancer-related deaths is lung cancer, of which more than 85% of cases are categorized as non-small cell lung cancer. The process of angiogenesis, which results in the formation of vasculature, is a complex and coordinated process that is required for cancer growth and metastasis. Pathways that promote angiogenesis have been targeted as a therapeutic approach in multiple types of cancer, including non-small cell lung cancer. Of these, the vascular endothelial growth factor pathway has been the most well studied, but more recently, the platelet-derived growth factor and fibroblast growth factor pathways have been identified as regulators of angiogenesis and potential mediators of resistance to vascular endothelial growth factor inhibition. Bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor, is currently the only antiangiogenic drug approved for the treatment of non-small cell lung cancer; however, several tyrosine kinase inhibitors that target vascular endothelial growth factor receptors as well as platelet-derived growth factor receptors and/or fibroblast growth factor receptors are being developed. This article reviews the role of the fibroblast growth factor and platelet-derived growth factor pathways in angiogenesis and provides a summary of dual (e.g., sorafenib, sunitinib) and triple (e.g., BIBF 1120, pazopanib) antiangiogenic tyrosine kinase inhibitors currently in development for the treatment of non-small cell lung cancer. (C) 2011 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据